X4 Pharmaceuticals’ (XFOR) Buy Rating Reaffirmed at HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $1.50 price target on the stock. HC Wainwright’s price target indicates a potential upside of 165.35% from the stock’s previous close.

Separately, Stifel Nicolaus reduced their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $0.57 on Tuesday. The company has a market cap of $96.41 million, a P/E ratio of -6.28 and a beta of 0.14. The firm’s 50 day moving average is $0.55 and its two-hundred day moving average is $0.62. X4 Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Verition Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $30,000. SG Americas Securities LLC acquired a new stake in X4 Pharmaceuticals in the 3rd quarter valued at $37,000. XTX Topco Ltd purchased a new position in X4 Pharmaceuticals in the second quarter valued at about $65,000. Rhumbline Advisers lifted its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after purchasing an additional 23,831 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after buying an additional 126,296 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.